SOM Biotech and Vall d’Hebron successfully complete a clinical trial in patients with TTR amyloidosis Blog Post

SOM Biotech and the Vall d’Hebron Research Institute (VHIR) have successfully completed a Phase IIa proof-of-concept clinical trial in humans to evaluate the efficacy and safety of an innovative oral therapy for transthyretin amyloidosis (TTA), a rare disease that affects the peripheral nervous system and heart. To carry out this trial, the hospital and the Catalan biotech, with headquarters at the Barcelona Science Park (PCB), signed an risk-sharing agreement under (RSA) which they jointly assumed the risks and economic returns of the project.